Search results for "carrier protein"

showing 10 items of 361 documents

Mutations in the PDS Gene in German Families with Pendred’s Syndrome: V138F Is a Founder Mutation

2003

Pendred's syndrome, an autosomal-recessive condition characterized by congenital sensorineural hearing loss and goiter, is caused by mutations in the PDS gene. Located on chromosome 7q22-q31, it encodes a chloride-iodide transporter expressed in the thyroid, inner ear, and kidney. We investigated the PDS gene of six affected individuals from four unrelated families with Pendred's syndrome by direct sequencing. PDS mutations were identified in homozygous or compound heterozygous state in all six cases. A homozygous missense mutation leading to the amino acid substitution S133T was detected in a family of Turkish origin. The mutations found in the other affected individuals, who originate fro…

MaleThreoninemedicine.medical_specialtyAdolescentTurkeyHearing Loss SensorineuralEndocrinology Diabetes and MetabolismClinical BiochemistryMutation MissenseBiologyCompound heterozygositymedicine.disease_causeBiochemistryGenetic determinismEndocrinologyHypothyroidismGermanyInternal medicineSerinemedicineHumansMissense mutationAlleleChildPendred syndromeGeneticsMutationBase SequenceBiochemistry (medical)HaplotypeInfant NewbornMembrane Transport Proteinsfood and beveragesSyndromemedicine.diseaseFounder EffectPedigreeEndocrinologyAmino Acid SubstitutionHaplotypesSulfate TransportersChild PreschoolMicrosatelliteFemaleCarrier ProteinsThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Effects of small interfering RNAs targeting fascin on human esophageal squamous cell carcinoma cell lines

2010

Abstract Background Fascin induces membrane protrusions and cell motility. Fascin overexpression was associated with poor prognosis, and its downregulation reduces cell motility and invasiveness in esophageal squamous cell carcinoma (ESCC). Using a stable knockdown cell line, we revealed the effect of fascin on cell growth, cell adhesion and tumor formation. Methods We examined whether fascin is a potential target in ESCC using in vitro and in vivo studies utilizing a specific siRNA. We established a stable transfectant with downregulated fascin from KYSE170 cell line. Results The fascin downregulated cell lines showed a slower growth pattern by 40.3% (p In vivo, the tumor size was signific…

MaleTime FactorsHistologyEsophageal NeoplasmsMice NudeApoptosismacromolecular substancesCysteine Proteinase InhibitorsBiologyTransfectionAmino Acid Chloromethyl KetonesPathology and Forensic MedicineExtracellular matrixMiceDownregulation and upregulationCell Line TumorCell Adhesionlcsh:PathologyAnimalsHumansRNA Small InterferingCell adhesionCell ProliferationFascinMice Inbred BALB CCell growthResearchMicrofilament ProteinsGeneral MedicineTransfectionCaspase InhibitorsXenograft Model Antitumor AssaysTumor BurdenCell biologyCell cultureApoptosisCaspasesCarcinoma Squamous Cellbiology.proteinRNA InterferenceCollagenCarrier Proteinslcsh:RB1-214Diagnostic Pathology
researchProduct

2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment.

2015

Elevated fetal hemoglobin (HbF) ameliorates the clinical severity of hemoglobinopathies such as β-thalassemia and sickle cell anemia. Currently, the only curative approach for individuals under chronic transfusion/chelation support therapy is allogeneic stem cell transplantation. However, recent analyses of heritable variations in HbF levels have provided a new therapeutic target for HbF reactivation: the transcriptional repressor BCL11A. Erythroid-specific BCL11A abrogation is now actively being sought as a therapeutic avenue, but the specific impact of such disruption in humans remains to be determined. Although single nucleotide polymorphisms in BCL11A erythroid regulatory elements have …

Malecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentImmunologyBiologyBiochemistrySettore MED/38 - Pediatria Generale E SpecialisticaRed Cells Iron and ErythropoiesisInternal medicinehemic and lymphatic diseasesFetal hemoglobinmedicineGene silencingHumansChildNervous System DiseaseFetal HemoglobinNuclear ProteinHematologyNuclear ProteinsCell BiologyHematologymedicine.diseasePhenotypeSickle cell anemiaUp-RegulationTransplantationRepressor ProteinsSettore MED/03 - Genetica MedicaChromosomes Human Pair 22p15-p16.1 microdeletions BCL11A HbF neurologicImmunologyFemaleStem cellChromosome DeletionNervous System DiseasesCarrier ProteinHaploinsufficiencyCarrier ProteinsHumanBlood
researchProduct

Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States.

2006

PURPOSE Glaucoma is characterized by a progressive loss of retinal ganglion cells that results in a characteristic optic neuropathy associated with visual field loss. In previous studies, changes in the antibody profiles have been shown in the sera of patients with glaucoma, and these findings suggest a role for autoimmune involvement in the pathogenesis of glaucoma in some patients. The purpose of this study was to compare the antibody profiles against optic nerve antigens in patients with glaucoma in two different study populations from Germany and the United States. METHODS One hundred twenty patients were included in the study, 60 from Germany and 60 from the United States: a control gr…

Malegenetic structuresOpen angle glaucomaBlotting WesternMolecular Sequence DataGlaucomaEnzyme-Linked Immunosorbent AssayNerve Tissue ProteinsRetinal ganglionAutoantigensGas Chromatography-Mass SpectrometryOptic neuropathyAntigenGermanymedicineHumansAmino Acid SequenceEye ProteinsIntraocular PressureAgedAutoantibodiesbusiness.industryMicrofilament ProteinsAutoantibodyMiddle Agedmedicine.diseaseeye diseasesUnited StatesImmunologyOptic nervePopulation studyFemalesense organsbusinessCarrier ProteinsGlaucoma Open-AngleInvestigative ophthalmologyvisual science
researchProduct

Low Protein Intake Is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population

2014

SummaryMice and humans with growth hormone receptor/IGF-1 deficiencies display major reductions in age-related diseases. Because protein restriction reduces GHR-IGF-1 activity, we examined links between protein intake and mortality. Respondents aged 50–65 reporting high protein intake had a 75% increase in overall mortality and a 4-fold increase in cancer death risk during the following 18 years. These associations were either abolished or attenuated if the proteins were plant derived. Conversely, high protein intake was associated with reduced cancer and overall mortality in respondents over 65, but a 5-fold increase in diabetes mortality across all ages. Mouse studies confirmed the effect…

Malemedicine.medical_specialtyLow proteinnutrition protein intake caloric restriction nutrientsPhysiologymedicine.medical_treatmentLongevityCalorie restrictionBreast NeoplasmsGrowth hormone receptorBiologyArticleMiceLow-protein dietNeoplasmsDiabetes mellitusInternal medicineDiabetes MellitusDiet Protein-RestrictedmedicineAnimalsHumansInsulin-Like Growth Factor IMelanomaMolecular BiologyAgedProportional Hazards ModelsMice KnockoutMice Inbred BALB CIncidence (epidemiology)CancerCell BiologyMiddle Agedmedicine.diseaseMiddle ageMice Inbred C57BLCross-Sectional StudiesEndocrinologyFemaleCarrier ProteinsFollow-Up StudiesSignal TransductionCell Metabolism
researchProduct

Mass Concentration of Plasma Phospholipid Transfer Protein in Normolipidemic, Type IIa Hyperlipidemic, Type IIb Hyperlipidemic, and Non–Insulin-Depen…

1999

Abstract —Mean plasma phospholipid transfer protein (PLTP) concentrations were measured for the first time by using a competitive enzyme-linked immunosorbent assay. PLTP mass levels and phospholipid transfer activity values, which were significantly correlated among normolipidemic plasma samples ( r =0.787, P <0.0001), did not differ between normolipidemic subjects (3.95±1.04 mg/L and 575±81 nmol · mL −1 · h −1 , respectively; n=30), type IIa hyperlipidemic patients (4.06±0.84 mg/L and 571±43 nmol · mL −1 · h −1 , respectively; n=36), and type IIb hyperlipidemic patients (3.90±0.79 mg/L and 575±48 nmol · mL −1 · h −1 , respectively; n=33). No significant correlations with plasma lipid p…

Malemedicine.medical_specialtyPhospholipidEnzyme-Linked Immunosorbent AssayHyperlipidemiasCarbohydrate metabolismchemistry.chemical_compoundReference ValuesPhospholipid transfer proteinInternal medicineDiabetes mellitusCholesterylester transfer proteinBlood plasmamedicineHumansPhospholipid Transfer ProteinsGlycoproteinsbiologyChemistryImmune SeraOsmolar ConcentrationMembrane ProteinsLipid metabolismmedicine.diseaseLipidsCholesterol Ester Transfer ProteinsType iibEndocrinologyDiabetes Mellitus Type 2biology.proteinFemaleCarrier ProteinsCardiology and Cardiovascular MedicineArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Binge drinking upregulates accumbens mGluR5-Homer2-PI3K signaling: functional implications for alcoholism.

2009

The glutamate receptor-associated protein Homer2 regulates alcohol-induced neuroplasticity within the nucleus accumbens (NAC), but the precise intracellular signaling cascades involved are not known. This study examined the role for NAC metabotropic glutamate receptor (mGluR)-Homer2-phosphatidylinositol 3-kinase (PI3K) signaling in regulating excessive alcohol consumption within the context of the scheduled high alcohol consumption (SHAC) model of binge alcohol drinking. Repeated bouts of binge drinking ( approximately 1.5 g/kg per 30 min) elevated NAC Homer2a/b expression and increased PI3K activity in this region. Virus-mediated knockdown of NAC Homer2b expression attenuated alcohol intak…

Malemedicine.medical_specialtyReceptor Metabotropic Glutamate 5Binge drinkingContext (language use)Mice TransgenicNucleus accumbensReceptors Metabotropic GlutamateNucleus AccumbensArticleWortmanninchemistry.chemical_compoundMicePhosphatidylinositol 3-KinasesHomer Scaffolding ProteinsInternal medicinemental disordersmedicineAnimalsEthanolEthanolMetabotropic glutamate receptor 5business.industryGeneral NeuroscienceAntagonistUp-RegulationMice Inbred C57BLAlcoholismEndocrinologyPhenotypechemistryMetabotropic glutamate receptorbusinessCarrier ProteinsNeuroscienceSignal TransductionThe Journal of neuroscience : the official journal of the Society for Neuroscience
researchProduct

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm,…

2013

Summary Background Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. We aimed to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with this disease. Methods We did a single-arm, open-label, phase 3 study of lomitapide for treatment of patients with homozygous familial hypercholesterolemia. Current lipid lowering therapy was maintained from 6 weeks before baseline through to at least week 26. Lomitapide dose was escalated on the basis of safety and tolerability from 5 mg to a maximum of 60 mg a day. The primary endpoint was mean percent change in levels of LDL cholesterol from baseline …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaMipomersenPhases of clinical researchSocio-culturaleFamilial hypercholesterolemialdl-apheresismtp inhibitorBenzimidazoleMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type IIchemistry.chemical_compoundlipid lowering therapyInternal medicineClinical endpointMedicinelomitapidebiologybusiness.industryCholesterolMedicine (all)Homozygotelomitapide; ldl-apheresis; lipid lowering therapy; homozygous familial hypercholesterolemia; mtp inhibitorGeneral MedicineCholesterol LDLhomozygous familial hypercholesterolemiamedicine.diseaseLomitapideEndocrinologyTolerabilitychemistrybiology.proteinFemalebusinessCarrier ProteinHuman
researchProduct

Dose-dependent metabolism and hepatic distribution of phenprocoumon in rats

1988

The dose-dependency of phenprocoumon disposition was determined in rats by iv administration of 0.1 and 1.0 mg/kg doses to separate groups of animals. The intrinsic clearance (unbound clearance) was 33% lower in the animals given 1.0 mg/kg dose than in the animals given 0.1 mg/kg dose. The apparent unbound volume of distribution was 55% lower and the elimination rate constant 54% higher in the high dose group than in the lower dose group. Binding of phenprocoumon to liver showed saturability with a two- to threefold higher apparent unbound fraction of phenprocoumon in liver in animals given the high dose in comparison to animals given the low dose.

Malemedicine.medical_specialtymedicine.drug_classDose dependencePhenprocoumonPharmacokineticsElimination rate constantInternal medicinemedicineAnimalsDistribution (pharmacology)Tissue DistributionPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsVolume of distributionDose-Response Relationship DrugChemistryAnticoagulantRats Inbred Strains4-HydroxycoumarinsMetabolismRatsEndocrinologyLiverInjections IntravenousPhenprocoumonCarrier Proteinsmedicine.drugJournal of Pharmacokinetics and Biopharmaceutics
researchProduct

Differential expression of suppressors of cytokine signaling-1, -2, and -3 in the rat hippocampus after seizure: implications for neuromodulation by …

2003

Numerous studies have investigated the expression of various cytokine families in the CNS after brain injury. The gp130 or interleukin (IL)-6-type cytokines have received a great deal of focus, and it is clear that they exhibit an acute and robust upregulation in various brain injury models. We are interested to determine, however, whether endogenously expressed cytokines in the CNS act in a direct neuromodulatory manner. In an accompanying study, we examined the expression of five gp130 cytokines and their receptors in the lithium-pilocarpine model of status epilepticus. We follow up that study here by trying to determine if gp130 signal transduction occurs in hippocampal principal neurons…

Malemedicine.medical_treatmentPopulationSuppressor of Cytokine Signaling ProteinsHippocampal formationBiologyNeuroprotectionHippocampusRats Sprague-DawleySuppressor of Cytokine Signaling 1 ProteinSeizuresmedicineAnimalsRNA MessengerReceptors Cytokineeducationeducation.field_of_studyGeneral NeuroscienceInterleukinGlycoprotein 130RatsDNA-Binding ProteinsRepressor ProteinsCytokineGene Expression RegulationSuppressor of Cytokine Signaling 3 ProteinTrans-ActivatorsCytokinesSignal transductionCytokine receptorCarrier ProteinsNeuroscienceSignal TransductionTranscription FactorsNeuroscience
researchProduct